# Xenon Pharmaceuticals (XENE) — News

XENE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/xene/news

## Recent headlines

- [OFCOM: Decided to focus the remainder of investigation on X's compliance with its illegal content and complaints and reporting duties](https://www.ainvest.com/news/ofcom-decided-focus-remainder-investigation-compliance-illegal-content-complaints-reporting-duties-2610) — AInvest Wire, Oct 14, 2026
  The UK's communications regulator, Ofcom, has announced that it will focus the remainder of its investigation on X's compliance with its obligations regarding illegal content and complaints and reporting duties. This decision follows an ongoing review of the platform's adherence to the Online…
- [Xenon Pharmaceuticals shares fall 23.5% after co pauses new enrollment in depression drug trials](https://www.ainvest.com/news/xenon-pharmaceuticals-shares-fall-23-5-pauses-enrollment-depression-drug-trials-2609) — AInvest Wire, Sep 18, 2026
- [Xenon Pharmaceuticals Inc.: Needham cuts target price to $60 from $78](https://www.ainvest.com/news/xenon-pharmaceuticals-needham-cuts-target-price-60-78-2609) — AInvest Wire, Sep 18, 2026
  Xenon Pharmaceuticals Inc. (NASDAQ: XENE) has seen recent adjustments in analyst price targets, with Needham lowering its target price for the stock to $78 from $80, maintaining a 'Buy' rating. This follows a broader trend of analyst activity, with 17 Wall Street analysts offering a consensus "Buy"…
- [Xenon Pharmaceuticals shares fall 27.5% premarket after co pauses new enrollment in depression drug trials](https://www.ainvest.com/news/xenon-pharmaceuticals-shares-fall-27-5-premarket-pauses-enrollment-depression-drug-trials-2609) — AInvest Wire, Sep 18, 2026
  Xenon Pharmaceuticals Inc. (XENE) shares fell 27.5% in premarket trading on September 18, 2026, following the company’s announcement that it has paused new enrollment in clinical trials for its depression drug candidate. The decision, which came without immediate explanation, has raised concerns…
- [Xenon Pharmaceuticals Inc: Voluntary action does not impact ongoing epilepsy studies](https://www.ainvest.com/news/xenon-pharmaceuticals-voluntary-action-impact-ongoing-epilepsy-studies-2609) — AInvest Wire, Sep 17, 2026
  Xenon Pharmaceuticals Inc. (XENE) has clarified that its recent voluntary action does not affect the ongoing clinical studies for its epilepsy treatments. The company emphasized that all trials related to its investigational therapies remain on schedule and unaffected by the decision[1]. The…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).